Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Wilms Tumor 1Multiple Myeloma 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Has results × Proteasome Inhibitors × Clear all
NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Sellas Life Sciences Group

Phase 1/2 Completed
20 enrolled 9 charts
GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡